REGNRegeneron PharmaceuticalsSigning up patients
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma (FL)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 822 (planned)
- Started
- Dec 12, 2023
- Main results expected
- Feb 7, 2028
- Fully finished
- Nov 3, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Dose-Limiting Toxicities (DLTs) for odronextamab
Measured over: Up to 35 days
Incidence of Treatment-Emergent Adverse Events (TEAEs) of odronextamab
Measured over: Up to 2 years
Severity of TEAEs of odronextamab
Measured over: Up to 2 years
Complete Response at 30 months (CR30) as assessed by independent central review
Measured over: Up to 30 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06091254 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC